T1	Pharmacological_substance 7 23	AUC2 carboplatin
T2	Disorder 27 69	acquired platinum-resistant ovarian cancer
T3	Pharmacological_substance 91 102	phenoxodiol
N1000 	Reference T3 MeSH:C471183	phenoxodiol
T4	Disorder 195 228	Platinum-resistant ovarian cancer
T5	Pharmacological_substance 503 514	phenoxodiol
N1001 	Reference T5 MeSH:C471183	phenoxodiol
T6	Pharmacological_substance 620 636	AUC2-carboplatin
T8	Pharmacological_substance 767 783	AUC2-carboplatin
T11	Pharmacological_substance 814 830	AUC2-carboplatin
T17	Disorder 1695 1715	hematologic toxicity
N1 	Reference T17 UMLS:C0600688	hematologic toxicity
T18	Pharmacological_substance 1805 1821	AUC2-carboplatin
T20	Pharmacological_substance 1864 1880	AUC2-carboplatin
T7	Disorder 230 234	PROC
T9	Pharmacological_substance 516 519	PXD
N1002 	Reference T9 MeSH:C471183	PXD
T10	Disorder 640 644	PROC
T12	Pharmacological_substance 758 761	PXD
N1003 	Reference T12 MeSH:C471183	PXD
T13	Disorder 851 855	PROC
T19	Subject 1174 1186	142 patients
T21	Subject 1103 1115	142 patients
T22	Pharmacological_substance 1603 1606	PXD
N1004 	Reference T22 MeSH:C471183	PXD
T23	Pharmacological_substance 1734 1737	PXD
N1005 	Reference T23 MeSH:C471183	PXD
T24	Disorder 1825 1829	PROC
T25	Disorder 1966 1970	PROC
T27	Combination 70 74	with
T28	Subject 104 141	a sensitizer of platinum cytotoxicity
T29	Pharmacological_substance 297 325	traditional cytotoxic agents
T30	Manner_cue 275 282	limited
T32	Subject 645 653	patients
T33	Pharmacological_substance 524 542	novel biomodulator
T35	Combination 599 607	combined
T38	Pharmacological_substance 693 700	placebo
N1006 	Reference T38 MeSH:D010919	placebo
T39	Subject 856 864	patients
T40	Pharmacological_substance 389 397	platinum
N1007 	Reference T40 MeSH:D010984	platinum
T41	Pharmacological_substance 801 808	placebo
N1008 	Reference T41 MeSH:D010919	placebo
T42	Combination 762 766	plus
T43	Combination 809 813	plus
T45	Subject 785 792	group 1
T46	Subject 832 839	group 2
T47	Subject 1301 1308	group 1
T14	Subject 1387 1394	group 2
T15	Subject 1679 1690	both groups
T16	Combination 1784 1792	combined
T49	Speculation_cue 1745 1756	no evidence
T51	Subject 1477 1484	group 1
T52	Subject 1492 1499	group 2
T53	Negation_cue 1896 1904	inactive
